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Background: Diabetes affects both individuals and their families and has an impact on economic and social
development of a country. Information on the availability, cost, and quality of medical care for diabetes is mostly
not available for many low- and middle-income countries including Bangladesh. Complications from diabetes,
which can be devastating, could largely be prevented by wider use of several inexpensive generic medicines, simple
tests and monitoring and can be a cost saving intervention. This study will provide an in-depth and comprehensive
picture of social and economic impacts of diabetes in Bangladesh and propose clear recommendations for improving
prevention and management of diabetes. The objectives of the study are:
1) To study the association between diabetes and other health problems and its social impacts
2) To estimate the economic impact of diabetes including total direct and indirect costs
3) To measure the impact of diabetes on quality of life among diabetes patients in Bangladesh
4) To study the impact of diabetes on the health care system
Methods: This is a case–control study comparing cases with type 2 diabetes to controls without diabetes matched
on age, sex and place of residence. 564 cases and 564 controls will be selected from the outpatient department of a
tertiary hospital in Dhaka, Bangladesh. Data on socioeconomic status, health utility index, direct and indirect costs for
diabetes, medication adherence, quality of life, treatment satisfaction, diet, physical activity, mental state examination,
weight, height, hip and waist circumference, blood pressure, pulse, medication history, laboratory data and physical
examination will be conducted.
Outcome measures: The primary outcome measures will be association between diabetes and other health
problems, cost of diabetes, impact of diabetes on quality of life and secondary outcome measures are impact of
diabetes on healthcare systems in Bangladesh.
Discussion: This study will provide an in-depth and comprehensive picture of social and economic impacts of
diabetics in Bangladesh and propose clear recommendations for improving prevention and management of diabetics.
It will help to develop programs and policies for better management of Diabetics and cost effective strategies in
Bangladesh context.
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Diabetes can lead to a variety of disabling, life-threatening,
and expensive complications, including stroke, heart at-
tack, renal disease, neuropathy, peripheral artery disease,
lower-limb amputation, and visual impairment. In 2011,
diabetes was associated with 4.6 million deaths worldwide,
causing more deaths than HIV and malaria combined
and consumed at least 465 billion current U.S. dollars in
health care resources [1,2]. Demographic transition, com-
bined with urbanization and industrialization, has resulted
in drastic changes in lifestyles globally. Consequently,
lifestyle-related diseases like diabetes have emerged as
major public health problems in the developing countries
[3-5]. Three-quarters of persons with diabetes live in
low- and middle-income countries [2] where more than
80% of diabetes related deaths occur. It is estimated that
by 2030, Bangladesh will be the 5th largest country in the
world in terms of population living with diabetes which
will be challenging its health system in terms of meeting
the demands of its population [2].
In Bangladesh, diabetes affects all segments of the
population and is one of the leading causes of premature
morbidity and mortality, and requires life-long health-
care services [6]. Poverty, low education, and gender
discrimination adversely affect women with diabetes
[7]. The levels of knowledge about diabetes among
the at-risk population and among those who suffer
from the disease are poor [3]. About 90% of all respon-
dents did not test their blood glucose regularly and suf-
fered from several complications with low medication
adherence and poor clinic attendance [3]. Information
on the availability, cost, and quality of medical care for
diabetes is generally not available in Bangladesh. Com-
plications from diabetes, which can be devastating,
could largely be prevented by wider use of several inex-
pensive generic medicines, simple tests and monitoring
and can be costs saving interventions in a country like
Bangladesh [8].
Diabetes imposes a considerable burden on health sys-
tems and societies [9]. The cost implications of diabetes
to society are multi-fold: direct costs to people with dia-
betes, their families and to the health care sectors, indirect
costs to society and government, which are the productiv-
ity costs; and intangible costs, which means adverse effects
on quality of life [10]. Very little is known about the eco-
nomic impact of diabetes in the developing world where
predicted increases in prevalence are highest [11]. With
increasing concern among providers about the rising costs
of health care, economic assessments of the impact of
various diseases are growing in importance [12]. In asses-
sing the economics of diabetes, however, a number of
questions must be addressed, including the definition and
measurement of incidence, the definition and meas-
urement of economic impact, and a method by whichincidence and economic impact may be linked [13].
Diabetes clearly affects individuals, families, providers of
medical care, and the governmental ministries that pay for
care. These effects probably also disable communities and
retard national economic growth. However, until basic data
have been gathered, the magnitude of these effects can
barely be estimated.
The economic and human costs provoked by diabetes
in a large population such as in Bangladesh will be sub-
stantial. However, despite these astounding numbers of
diabetes population in Bangladesh which is expected to
rise to more than 16 million by 2020 [2], there are little
evidence based research on the social and economic
impact of diabetics in Bangladesh. In this context, we
propose to conduct a first-ever comprehensive case–
control study of social and economic impact of diabetes
in Bangladesh.
Hypothesis
1. The total annual per-person expenditures for medical
care among persons with diabetes would exceed total
annual per-person expenditures among persons
without diabetes.
2. The quality of life for people without diabetes would
be better than people with diabetes.
Objectives
The main objective of this study is to describe the social
and economic impact of diabetes in Bangladesh, in-
cluding out-pocket expenditures by patients and their
families; other expenditures for medical care; impact
on quality of life, disability and health utility; impact on
the income, employment, education, and property of
patients and their families; and the efficiency of medical
care received for diabetes. The specific objectives are
as follows:
1) To study the association between diabetes and other
health problems and its social impacts
2) To estimate the economic impact of diabetes
including total direct and indirect costs
3) To measure the impact of diabetes on quality of life
among diabetes patients in Bangladesh
4) To study the impact of diabetes on the health care
system
Methods
This is a case–control study comparing cases with type
2 diabetes to controls without diabetes matched on age
and sex. The case–control study design isolates the costs
caused by diabetes by revealing differences and ratios be-
tween persons with diabetes and matched controls. The
method solves the otherwise very difficult problem of
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admission that are partly caused by diabetes but also
partly due to other causes.
Data will be obtained by personal interviews with the
cases and controls. Interview data will be supplemented
with data from health facilities to more fully describe the
subjects’ costs of care. Searching of health facility re-
cords will be based on personal-interview responses that
indicate when and where subjects have received medical
care. The form for unit costs data collection from health
facilities will be piloted in a similar setting in Bangladesh
before the study. All subjects will provide informed con-
sent prior to being interviewed and having their health
facility records examined.
Study population
This study will be carried out among patients attending
the outpatient department of the Bangladesh Institute of
Research & Rehabilitation in Diabetes, Endocrine and
Metabolic Disorders (BIRDEM) Hospital. BIRDEM has
the largest diabetic Out-Patient Department (OPD) turn-
over in the world under a single roof and it has an In-
Patient hospital with about 700 beds with all modern
disciplines of medicine [14]. BIRDEM is the only na-
tional level tertiary health care and research institute for
diabetes in Bangladesh and recognized as WHO collab-
orating center for research on prevention and control of
diabetes. The OPD of BIRDEM currently has 497756
registered diabetes patients and serves more than 4000
patients daily [15]. Patients come here for treatment
from all over the country. The average number of pa-
tients per day in the BIRDEM OPD will be sufficient to
cover the total sample size of this study within the given
time frame.
Sample size and statistical power
Calculations of the economic impacts of diabetes on in-
dividuals cannot adequately describe the burden or im-
pact on social and national economics of diabetes, for
three reasons. First, their assessments of the economic
burden of diabetes are confounded by competing risks
and co-morbidities. Because there are common risk fac-
tors that increase one’s risk of multiple diseases (e.g.
tobacco use or obesity that could be linked to diabetes,
heart disease or cancer), unadjusted estimates of the
economic burden attributed to any one condition are
likely to be upwardly biased. Second, socioeconomic and
demographic differences across households can influ-
ence healthcare expenditures and other coping strategies
in response to illness. Finally, aggregate calculations also
include impacts of diabetes on households unaffected
by diabetes, such as via an overall slowing of economic
growth that lowers employment rates and incomes [16].
Considering all these options, we focused specifically onselecting cases with diabetes and age group, sex and
place of residence matched controls. We used the fol-
lowing formula to calculate the number of cases and
controls [17]:
n ¼ r þ 1
r
 
σ2 Zβ þ Zα=2
 2
differenceð Þ2
– For 80% power, Zβ=.84
– For 0.05 significance level, Zα=1.96
– r = 1 (equal number of cases and controls)
– σ=12.0 (Standard Deviation of the outcome variable)
– Difference = 2.0 (Effect size of the mean difference)
n ¼ 2ð Þ 12
2 7:84ð Þ
2ð Þ2 ¼ 2ð Þ6
2 7:84ð Þ ¼ 564
n = 564 (564 cases and 564 controls)
Therefore, we will recruit a total 1128 participants (564
cases and 564 controls) for this study which should be
sufficient to conduct different sub-group analysis to meas-
ure the economic burden of diabetes across different
socio-economic groups.
Primary outcome measures
 Association between diabetes and other health
problems (Questionnaires)
 Cost of diabetes (Questionnaire and statistical
modelling)
 Impact of diabetes on quality of life (Questionnaires
and statistical modelling)
Secondary outcome measures
 Impact of diabetes on health care systems
(questionnaires and statistical modelling)
Inclusion and exclusion criteria
Eligibility
Ages: 20–60 years, Genders: All genders.
Inclusion criteria for cases
 Diagnosed as type 2 diabetic patient at BIRDEM
OPD according to WHO criteria
 Willing to answer the questionnaire and provide
anthropometric measurements
 Willing to have health records checked by the study
team
 Providing written informed consent.
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 Cases younger than 20 years or older than 60 years
 Patients with serious co-morbid conditions requiring
immediate hospitalization or having mental illness
 Patients unable to give their informed consent
Inclusion criteria for matched controls
 Individuals with similar sex and age range (within
5 years band) with cases
 No history of diabetes
Exclusion criteria for controls
 A known previous history of any diabetes (self-reported
or physician diagnosed)
 Unable to provide consent.
Sampling design
Case selection and recruitment
Cases with diagnosed diabetes will be selected from the
Bangladesh Institute of Research on Diabetics, Endocrin-
ology and Metabolism (BIRDEM) Hospital outpatient
department (OPD) where patients from all over Bangladesh
comes for management of diabetes and its complications.
We will identify cases with diabetes from consecutive
patients as they come for treatment. Potential subjects will
be asked if they are willing to participate in the study and,
if so, a time and location for a personal interview will be
arranged and contact information gathered.
Selection and recruitment of control subjects
Controls will be individuals ‘frequency-matched’ to cases
on age (within 5 years band) and sex (male or female),
without a self-reported history of diabetes (or diagnosed
as diabetes by a physician). They will be recruited
within 48 hours of recruiting the index case, from
either (i) the same geographical residence of cases,
or (ii) visitors of patients attending the out-patient
department, or (iii) non-blood related visitors of index
diabetes cases, in the same hospitals,. All controls will
undergo identical study questioning and examination as
cases. One completed control interview will be obtained
for each case interview.
While we are recruiting case subjects and scheduling
personal interviews, we will ask cases who have said they
want to participate to identify five persons living closest
to him or her who are of the same age (+/− 5 years) and
sex. For each of these potential control subjects, we will
ask the case to provide whatever contact information
that he or she can. Cases will be assured that their
health information will not be shared with the control.
We will then randomly order the names on the resultinglist of five and approach each of these individual’s house-
holds in order, by telephone if possible or, if not, by visit-
ing their households. If the first-ordered individual is at
home, the interviewer will recruit this individual on the
spot and obtain informed consent and complete the
interview immediately if this is practicable. Otherwise,
if the individual is not willing to be interviewed at the
moment, an appointment for a later time will be made.
If the first-ordered individual is at home but does not
wish to participate, the interviewer will proceed to the
household of the second-ordered individual and repeat
the process.
If the second-ordered individual is not at home, the
interviewer will attempt to get telephone contact infor-
mation for this person so that recruitment can occur by
phone at a later time, and an interview scheduled. Inter-
viewers should not leave the area where they recruited
the case without a lead to a potential control. If by the
second household the interviewer has not recruited and
interviewed a control, she/he will proceed to each of the
remaining households to obtain contact information and
gauge potential interest.
The approach described above is chosen because it
can potentially achieve a balance between feasibility and
scientific rigor and should be scalable in Bangladesh. By
contrast, whereas use of population-based community
controls may be desirable in principle, it is considerably
more labour-intensive and expensive and cannot guaran-
tee that such controls will necessarily represent the
catchment areas from which hospital-based cases are de-
rived, particularly since referral patterns to hospitals are
complex. Furthermore, as controls in this study will be
drawn from visitor of patients attending the out-patient
department and non-blood related visitors of diabetes
cases, it is expected that such approach would minimize,
at least in part, major limitations involved with conven-
tional hospital-based controls if we cannot recruit com-
munity based controls.
Use of surrogates
When a case or control subject is not able to speak or
recall sufficiently completing the interview on their own,
the participation of surrogate respondents will be allowed.
The interviewer will ask another family member to answers
the survey questions on behalf of the respondent. The
name of the family member who answered the questions
will be written in the survey and the surrogate code
entered on the survey.
Non-response, non-completion, termination
If it proves impossible to complete an interview once it
has begun, and it cannot be completed on another day,
this case or control will be removed from the study sam-
ple and replaced with another person per protocol. They
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to terminate an interview prior to completion, the same
procedures will be followed as for a non-completer. All
data except for recruitment information obtained prior to
commencing the interview will be destroyed. The inter-
viewer will terminate the interviews of all control subjects
who say that they have been diagnosed with diabetes, or
whenever in the interviewer’s judgment the subject is not
responding truthfully or accurately or no longer wishes to
participate in the study.
Data collection tools
The research tools and instruments will include pre-
defined questionnaires, anthropometric measurements,
laboratory and medication lists, and physical examin-
ation. We will use the research tools developed by the
International Diabetes Federation (IDF) Health Eco-
nomic Group and translate them into Bengali as per
WHO standards. All interviews will be conducted by
trained interviewers under the supervision of a Research
Physicians.
Hospital data gathering tools: Information on cost
incurred by the hospitals is a vital component of illness
costs. Information on treatments received by patients
during their hospital visits is also critical in understand-
ing utilization of health care. To generate cost incurred
by third parties and to gather hospital information, we
have developed a hospital unit costs tool to gather infor-
mation on average costs including those incurred by
third parties (by type and reference level of the hospital
or outpatient clinic).
Estimation of expenditures for medical care will be
based on participant recall to ascertain charges for medi-
cines, supplies, and medical care services. To increase
accuracy of recall, the interview schedule will only ask
about events occurring only during the previous 90 days
and attempt to improve temporal accuracy by asking
respondents to name and associate a well-remembered
event that had occurred approximately 90 days previously.
To estimate expenditures for medicines, interviewers will
ask subjects about their most recent purchase of each of
the medicines they were currently using. For overnight
admissions to hospital and OPDs, respondents will be
asked to recall their total point-of-service payment,
including charges for medicines and tests received or, if
they paid only a portion out of pocket, the total bill or
charge. Total charges per visit or hospital admission usu-
ally includes charges for medicines because doctors and
hospitals typically use pharmaceutical sales as a primary
means to finance operations. This subset will be used to
estimate the characteristics of all events of the same
kind, including mean length of hospital stay and mean
payments per admission, per OPD visits, and per pur-
chase of medicine.Field testing
The research instruments and questionnaires and will be
translated in Bengali and field tested in a similar setting
to our current study site and population like the out-
patient department of Bangladesh University of Health
Science (BUHS) Hospital, Mirpur, Dhaka before con-
ducting the research. 25 cases and 25 control subjects
will be enrolled in the field testing. Feedback from the
field testing will be used to improve the language and
contents of the questionnaire and tools.
General outline plan for field work/data collection
On a typical day, the field staff will be present at the study
site early in the morning when patient registration starts in
the BIRDEM OPD. Registered patients who agree to par-
ticipate in the study will be referred by the physician on
duty to the study team. The study team will explain about
the study in details to the participants and request for sign-
ing the informed consent to all who agree to participate in
the study on a volunteer basis. The study team will also
collect data from one control against one case.
On an average, 5–6 patient forms should be completed
at the study site every day and the total data collection
should be completed by 12 months. At the end of the
day all team members will ensure that the completed
data collection forms and instruments are properly
stored in the field site. Data will be entered in an excel
sheet in an ongoing basis. A log book of all participants
with codes will be maintained by the study team. Written
informed consent will be obtained from all participants
that they agree to participate in the study voluntarily and
are free to stop participating at any point of the study.
Follow-up plans
Quality Monitoring and Assurance: Data collection forms
will be checked on a daily basis to ensure complete and
accurate data entry by field research workers. Cross
checking of data collection forms will be performed in
the fields under supervision of the Research Officer for
inconsistency and missing data. The Principal Investiga-
tor (PI) will be responsible for carrying out periodic data
checks and he will look for systematic patterns, errors,
scheduling problems or incomplete forms to provide
feedback to the study nurse and to ensure integrity of
data captured. Every week when the team meets, the PI
will pick 2 questionnaires filled in the current week by
one interviewer. The PI will go through the question-
naire, question by question with the entire team, to
identify incomplete/missing entries and any errors. The
purpose of this is to rectify and clear any doubts which the
interviewers may still have.
The PI will visit the fields at least once every week
and observe complete data collection by the field re-
search assistants. He will provide his feedback and
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Co-Investigators will also visit the field site without
prior notice to monitor data collection, physical measure-
ments and biological sample collection, transportation,
storage and analysis in accordance with the protocol. The
instruments for physical measurements will be regularly
calibrated according to guidelines of its manufacturers in
the fields and a written record maintained which will be
periodically checked by the PI for consistency and valid-
ity of data.
We will attempt to replicate interview and physical
measurements in a random sub-set (~5%) of the sample
to evaluate repeatability. For repeatability studies, we
will have about 50 participants, 25 cases and 25 con-
trols, with duplicate measures which will be sufficient
to estimate kappa coefficients of agreement of inter
and intra-observer reliability with a high degree of
precision even for categorical variables. The partici-
pants will be selected among study participants who
come to BIRDEM OPD for treatment and follow up and
agree for the process.
Description of variables
 Socio-demographic and economic information: We
will collect data on participant’s age, sex, religion,
education, marital status, occupation, income, family
size, family income, objects owned
 Knowledge of prevention, management and
complications of DM: Levels of knowledge and
perceptions of diabetics, Risk Factors for diabetics,
knowledge about prevention, management and
complications of diabetics.
 Self-perceived Quality of Life (OoL): This will be
measured using EQ-5D 3 L, which is a standardised
instrument for use as a measure for health outcome.
It is widely used, and by many governments a
recommended instrument for measuring health
related QoL [18].
 Self-reported diseases: This will be based on
self -reported information on diabetes, cardiovascular
diseases, renal disease, stroke, arthritis, chronic
respiratory disease, mental and physical disability by
the study participants.
 Medical History: Any known history of diabetes and
its type, CVD, hypertension, cancer,
hypercholesterolemia, stroke, kidney diseases, other
vascular disease, infectious disease, major surgery.
 Tobacco Use (WHO modified): A modified WHO
questionnaire on use of different forms of tobacco
currently and in the past will be recorded. Expenditure
on tobacco use will also be recorded [19].
 Physical Activity (GPAQ): WHO GPAQ questionnaire
which has been validated in the fields will be used tocapture information on different forms of physical
activity in MET which will be analyzed as per data
analysis protocol [20,21].
 Diet: A modified WHO STEPS questionnaire will be
administrated to ascertain food consumption pattern
and dietary choices, type and frequency of
consumption of different foods.
 Health seeking behavior: Data will be collected on
type of health care practitioner visited during the
past year, number of visits, distance travelled for
consultation and expenditure for health.
 Use of medical services: Hospital and non hospital
visits for health problems, medical tests performed.
 Impact of health problems: affecting personal and
family life.
 Diabetes history: description of diagnosis, duration,
self-management of diabetes.
 Mental health status (Patient Health Questionnaire,
PHQ9): The PHQ 9 which is a standard toll for
collecting mental health status in primary health
care setting will be used in this study[22,23].
 Life events and Disability: Life events related
questions like new job, marriage, separation, injury,
accident in the family will be asked, which will be
based on validated questionnaire.
 Anthropometric Measurements: Weight, Height,
Waist and Hip circumference, Blood Pressure (BP),
Pulse rate will be measured.
 Laboratory data: data on HbA1c, FBS, 2HAFB, S.
Creatinine, Lipid Profile, ECG will be collected from
patient record book as available.
 Physical examination: General examination of eyes,
foot and neurology tests performed by a specialist
will be recorded.
Details about physical measurement
Measurement of blood pressure and pulse rate
Blood pressure is taken to determine the prevalence of
raised blood pressure in the population. We will use
Omron SEM-1 (Omron, Matsusaka Co., Japan) digital
blood pressure measurement instrument which is widely
used for research purpose in the community. Both sys-
tolic and diastolic blood pressure will be measured for
each participant. Three repeated measurements will be
recorded after an interval of 5 minutes alternating right
and left hand.
Height
Height will be measured for all participants using port-
able stadiometer. Standing height is measured with the
subject in bare feet, Back Square against the wall and
eyes looking straight ahead. A set square resting on the
scalp and a tape measurement from the wall/bed is used
to measure height to the nearest 0.5 cm.
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The weight of eligible participants will be taken to help
calculate their body mass index (BMI), which is their
weight relative to their height, and therefore to deter-
mine the prevalence of overweight and obese people in
the population. Weight is measured in undergarments
using a digital platform scale, to the nearest 100 grams.
Waist circumference
Waist circumference is measured to the nearest 0.1 cm
using a non-stretchable standard tape measure attached to
a spring balance exerting a force of 750 gm. Take measure-
ment over the unclothed abdomen at the smallest diameter
between the costal margin and the iliac crest. The tape
measure must be kept horizontal for standing measure-
ment. Subject should relax with arms held loosely at sides.
Hip circumference
Hip circumference is measured to the nearest 0.1 cm
using a non-stretchable standard tape measure attached
to a spring balance exerting a force of 750 gm. Take
measurement over light clothing at the level of the
greater trochanters (usually the widest diameter around
the buttocks). The tape measure must be kept horizontal
for standing measurement.
Data analysis
All data forms and questionnaires will be checked for er-
rors and necessary corrections will be made before data
entry. Data will be entered using data entry programme
with built in range and consistency checks. Frequency
distributions will be run to identify outliers. In all ana-
lysis, potential confounding variables and effect modifiers
will be considered. Descriptive analysis will be performed
for all variables and unadjusted comparisons between
case and control will be made using T-tests (for continu-
ous variables) or Chi-square Tests (for discrete variables).
When appropriate, longitudinal models will be created
for outcome variables. All data will be presented before
and after adjustment for confounding and interaction.
Basic presentations of data will include number and per-
centages of cases with diabetes by age, sex, location of
residence, and in relation to different known risk factors.
Chi-square tests will be used to assess the association be-
tween diabetes and different risk factors. Prevalence odd
ratios will be calculated for diabetes adjusted for major
confounding variables (e.g. age, sex, smoking habits, so-
cioeconomic status, nutritional status, and family history
of diabetes). Interaction between age and risk factors,
obesity and diabetes risk factors, and nutritional status
and risk factor (hypertension and diabetes risk factors)
will also be examined in the logistic regression model. All
statistical analyses will be done using SPSS (Version 20
from SPSS corporation, USA).Estimation of expenditures for medical care: The mean
length of hospital stay and mean payments per admis-
sion, per Out Patient Department (OPD) visits, and per
purchase of medicine will be calculated. Calculation of
annual medical expenditures: Annual rates of use of
medical services will be calculated by multiplying the
amounts self-reported for the preceding 90 days by 4.
We will calculate 90-day OPD expenditures separately
for visits made by a participant to hospital clinics, to the
private offices of doctors, to pharmacies, and to commu-
nity health workers.
We will calculate an average daily price, using data
about the price paid the most recent time the item was
purchased, the number of pills or units of insulin pur-
chased at that time, and the number of pills or units pre-
scribed per day. We will then multiply this result by an
adjuster for self-reported adherence, the average number
of days per week that the participant indicated that he
or she adhered to the prescribed regimen for a given
medicine, divided by seven to get the payment per day
“as used.” Mean daily payments will be multiplied by 30
to obtain a monthly mean expenditure and by 365 to ob-
tain an annual mean expenditure. Payments for glucose
testing strips will be calculated similarly to payments for
medicines except that self-reported testing rates (times
per day x days per week or month) to be used in lieu of
prescribed usage rates and adherence to obtain mean
daily, monthly, and annual usage and expenditure.
We will calculate total expenditures for medicalcare
per person as the sum of estimated annual payments per
person for inpatient hospital admissions, annual pay-
ments per person for OPD, annual payments per person
for medicines, and annual payments per person for
glucose-testing supplies. To avoid double counting, be-
cause self-reported payments for OPDs and admissions
included payments for medicines, we will subtract from
the grand total payments for medicines and strips that
were purchased from hospitals during visits and admis-
sions. Based on patient self-report, we will calculate the
proportion of hospital, clinic, OPD visits during which
medicines were purchased.
Hypothesis Testing: We will use a two-step “hurdle”
model to test for differences between persons with DM
and persons without DM. Using multivariable logistic re-
gression models that included case status (with DM =1,
with Non-DM =0), the team first test for differences in
the proportion of subjects with a non-zero value, e.g.,
persons with any OPD visits during the preceding
90 days, controlling for continuous age, sex, and urban
vs. rural residence as well as case. Age will be entered as
a linear continuous variable because the addition of other
transformations on age, e.g., age squared, will not signifi-
cantly improve the performance of the model. Then, a
second identically specified multivariable model on the
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gression model depend on the underlying distribution of
values: for counts of admissions, OPDs, and medicines, a
Poisson regression model will be used, while for average
length of hospital stay and costs per event, we will use or-
dinary least squares. The hurdle approach does not yield
a single overall coefficient or confidence interval for hy-
pothesis testing. However, if the coefficient on DM status
is positive and significantly different from zero in one
model and positive and not significantly different from
zero in the other model, or if both models are signifi-
cantly positive for DM, then the two models together
may be considered statistically significant. As our pri-
mary hypothesis is one-sided, we will use one-sided tests
to assess significance.
Healthcare use and expenditures: Absolute results for
health care use and costs associated with DM can be
estimated by subtracting age-, sex-, and location ad-
justed estimates for persons with Non-DM from the
relevant unadjusted results for persons with DM. How-
ever, for purposes of comparing results from this study
to the results of other studies conducted in other places
and times, a more robust statistic is the adjusted ratio
of costs or use among persons with DM to those
among persons with Non-DM (DM: Non-DM ratio).
Ratios are much less influenced than absolute differ-
ences by variations in source data, recruitment bias,
differences in economic systems, conditions and pat-
terns of medical practice, and currency fluctuations.
DM: Non-DM ratios will be calculated. Analysis of use
of effective diabetes care: Estimates of the percentage
use of essential medicines and other percentage mea-
sures of quality and access to medical care will be cal-
culated only for persons with DM. Associations with
categories of age and length of time since diagnosis of
DM will be tested for statistical significance using mul-
tivariable logistic regression models with continuous
age, sex, urban vs. rural residence, and continuous
duration of DM as predictors.
Ethics
All participants will be explained about the objectives
and importance of the research before recruitment. Par-
ticipation will be completely voluntary and an appropri-
ate written informed consent will be obtained from all
participants. All data-set containing information on the
participant will be locked at icddr,b and access to these
files will only be given to the PI’s, and the data-manager.
Publications and scientific presentations of the findings
from the study will be presented in aggregates and iden-
tity of individual participants will be kept confidential.
The study has received Research Review Committee
and Ethical Review Committee clearance from icddr,b
PR-13062.Discussion
This study will provide an in-depth and comprehensive
picture of social and economic impacts of diabetics in
Bangladesh and propose clear recommendations for
improving prevention and management of diabetes. It
will help to develop programs and policies for better
management of diabetes and cost effective strategies in
Bangladesh context. This study will generate evidence
based strategies for formulation policies and programs
targeting the general poor patients who cannot afford to
pay for the management of diabetes. It will also benefit
the women diabetes patients by identifying barriers to
access to healthcare, impact of diabetes on individual,
family and national levels and its economic impacts and
suggest remedies how to overcome these barriers.
The main limitations of this study are the recall bias
by cases and controls about several costs associated with
disease and hospitalization. Some participants might fail
to differentiate costs for treatment of each individual
items mentioned in the questionnaire which might affect
the results of the study. However, we will perform hospital
audits and collect information from multiple sources to
verify the correctness of information provided.
The social and economic impact of diabetes study in
China shows point-of-service payments or charges are
3.97 times higher among persons with diabetes than
among non-diabetes persons, which is higher than pub-
lished ratios for similar comparisons in developed coun-
tries [24]. The study suggests that the human and
economic impact of diabetes might be much greater in
the developing countries, where 75% of people with dia-
betes worldwide live, than in the industrialized world
where diabetes is diagnosed much earlier and essential
effective medicines are more widely prescribed. For a
developing country like Bangladesh, the economic costs
of diabetes is expected to be huge and with increasing
prevalence this will pose a serious threat to the health
systems and national economics. As Bangladesh Govern-
ment has started to decentralize the health systems with
inauguration of several primary care centres at the vil-
lage levels, it is imperative that these structures should
be equipped to deal with diabetes screening, primary
management and build awareness [25]. Diabetes medica-
tion is not available in the health center and health
workers are not trained to identify early complications.
However, to the best of our knowledge a national action
plan for diabetes has not yet been developed by the
Government. As diabetes is a costly condition which can
be prevented, the results of this study will help allocate
resources for prevention and control of diabetes and create
greater awareness among policy makers and clinicians.Competing interest
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